Point-of-Care Anti–CD19-CAR T-cell Therapy Induces Renal Remission in Refractory Myeloperoxidase–Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
Christian Schultze‐Florey, Vega Gödecke, Lisa Knoll, Krasimira Aleksandrova, Lubomir Arseniev, Jana Leise, Stephan Klöß, Kalin Stoyanov, Rodrigo Gutierrez Jauregui, Jan Hinrich Bräsen, Bernhard M.W. Schmidt, Florian H. Heidel, Kai M. Schmidt‐Ott, Robert Greite
Abstract
We report administration of anti-CD19 CAR-T cells to induce remission in a 64-year-old Caucasian male with refractory MPO-positive ANCA-associated vasculitis (MPO-AAV) with kidney involvement. MPO-AAV with kidney biopsy-proven crescentic glomerulonephritis was diagnosed four years earlier. Despite treatment courses including high-dose steroids, cyclophosphamide (cumulative dose 15 g), rituximab and avacopan (Fig. 1A), the patient exhibited refractory disease with persistently elevated MPO titers (Fig.